Lenalidomide Clinical Trials
Here are the 6 most popular medical studies for lenalidomide
Proteasome Inhibitor
BLd Combination Therapy for Multiple Myeloma
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is testing a new combination therapy for multiple myeloma. The goal is to find the highest dose of the combination that can be given safely, and to see how well it works in newly diagnosed patients.
Monoclonal Antibodies
Combination Therapy for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Anchorage, Alaska
This trial is studying a combination of rituximab, bortezomib, bendamustine, and lenalidomide to see how well it works compared with rituximab and bendamustine, followed by rituximab alone or with lenalidomide, in treating mantle cell lymphoma.
Popular filter options for lenalidomide trials
Phase 3 Clinical Trials
View 97 phase 3 medical studies.
Alkylating agents
Melphalan + Prednisone + Thalidomide/Lenalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial compares melphalan/prednisone with thalidomide to melphalan/prednisone with lenalidomide to see which is more effective in treating newly diagnosed multiple myeloma.
Clinical Trials With No Placebo
View 97 medical studies that do not have a placebo group.
Immunomodulatory Agent
Lenalidomide +1 More for Chronic Lymphocytic Leukemia
Recruiting3 awardsPhase 2
La Jolla, California
The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC). The purpose of this study is to determine the response rate of the combination of Revlimid® and Rituximab in previously untreated CLL patients in two arms- those aged 65 years and above and those younger than 65. Secondary objectives will evaluate the safety of the combination of Revlimid® and Rituximab, response duration, improvement in hematologic parameters, and the significance of the tumor flare reaction. All patients will have assessment of known prognostic factors for CLL as well as novel prognostic factors will be evaluated for predicting response to treatment. Biologic corollary studies are designed to evaluate the mechanism of Revlimid® in CLL and the combination of Revlimid® and Rituximab.
Alkylating agents
Melphalan + Prednisone + Thalidomide/Lenalidomide for Multiple Myeloma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial compares melphalan/prednisone with thalidomide to melphalan/prednisone with lenalidomide to see which is more effective in treating newly diagnosed multiple myeloma.
View More Lenalidomide Trials
See another 82 medical studies focused on lenalidomide.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.